Job Trends
Specifically, the new approval was for adults with dMMR recurrent or advanced solid tumors who have progressed on or after previous treatment and who have no satisfactory alternatives.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Looking for a biopharma job in Boston? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
THE LATEST
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
It was another busy week for clinical trials. Here’s a look.
While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, Keytruda is set to take the number-one position.
Collaboration will leverage Lantern’s proprietary AI platform and NCI’s platform to better predict patients’ tumor responses to specific drug classes and therapeutics
Using cloning technology to aid in the understanding of the evolution of cancers, Frank McKeon, professor of biology and biochemistry and director of the Somatic Stem Cell Center at the University of Houston, is leading a team to recreate the sequence leading to esophageal cancer.
The opportunity to do interesting and meaningful work continues to be more valuable than money, according to more than 2,700 life science professionals who took BioSpace’s 2019 Ideal Employer survey.
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
Eosera gives a sneak peek into new products and announces the move to a bigger location due to rapid growth.
Neos Therapeutics, Inc. announced that Jerry McLaughlin, chief executive officer, will present a company overview at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 9:30 a.m. ET in New York, NY.
Current Chief Executive Officer Albert Bourla will succeed Read as chairman on Jan. 1, 2020 and will continue to serve as CEO.